Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the formula (I):



(I)

wherein

~~(i) X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative, or~~

~~(ii) X represents C-CF_3, Z represents CH, and Y represents nitrogen, forming a 4-trifluoromethylpyridine derivative, or~~

(iii) Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein R_1 and R_2 are each, independently, selected from a group A consisting of



or from a group B, consisting of aryl-C_1-C_6-alkyl, aryl-C_1-C_6-alkoxy, heteroaryl-C_1-C_6-alkoxy, aryloxy-C_2-C_6-alkoxy, heteroaryloxy-C_2-C_6-alkoxy, 1-indanyloxy, 2-indanyloxy, aryloxy, heteroaryloxy, arylthio, heteroarylthio, C_5-C_6-cycloalkylthio, C_5-C_8-alkoxy, C_5-C_8-alkylthio, C_3-C_6-alkynyloxy, C_3-C_6-alkenyloxy, fluoro-C_2-C_4-alkoxy, C_4-C_8-cycloalkyloxy, C_3-C_8-cycloalkyl-

C_1-C_4-alkoxy, halogen, aryl-C_1-C_4-alkylthio, heteroaryl-C_1-C_4-alkylthio, aryl-C_1-C_4-alkylamino, heteroaryl-C_1-C_4-alkylamino, heteroaryl and aryl;

with the proviso that:

(i) R_1 and R_2 are different and are not both selected from group A or group B at the same time;

~~(ii) when both X and Z are CH and Y is N in formula (I), forming a pyridine derivative, and R_1 is 1-piperazinyl or 4-methylpiperazin-1-yl, then R_2 is other than 2-phenylethyl, benzyloxy, benzylamino, phenylthio, phenoxy, substituted phenoxy, C_4-C_8-cycloalkyloxy and C_3-C_8-cycloalkylmethoxy;~~

(iii) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R_2 is 1-piperazinyl, then R_1 is other than phenoxy, phenyl or phenyl substituted by bromo, and C_5-C_8 alkoxy; and when R_2 is 4-methylpiperazin-1-yl or 4-(2-hydroxyethyl)piperazin-1-yl, then R_1 is other than 5-nitro-2-furyl;

(iv) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R_1 is 1-piperazinyl, then R_2 is other than C_5-C_8 alkoxy;

and where R_3 is H or C_{1-4}-alkyl, allyl, 2-hydroxyethyl, 2-cyanoethyl, or a nitrogen protecting group~~, or a prodrug moiety~~;

R_4 is hydrogen, or C_{1-4} alkyl;

and wherein any aryl or heteroaryl residue, alone or as part of another group, in R_1 or R_2 may be independently substituted in one or more positions, by C_{1-4}-alkyl, C_{1-4}-alkoxy, C_{1-4}-alkylthio, C_{2-4}-acyl, C_{1-4}-alkylsulphonyl, cyano, nitro, hydroxy, C_{2-6}-alkenyl, C_{2-6}-alkynyl, fluoromethyl, trifluoromethyl, trifluoromethoxy, halogen, -N(R_5)(R_6), aryl, aryloxy, arylthio, aryl-C_{1-4}-alkyl, aryl-C_{2-4}-alkenyl, aryl-C_{2-4}-alkynyl, heteroaryl, heteroaryloxy, heteroarylthio or heteroaryl-C_{1-4}-alkyl, aryl-C_{1-4}-alkoxy, aryloxy-C_{1-4}-alkyl, dimethylamino-C_{2-4}-alkoxy; and

wherein any aryl or heteroaryl residue as substituents on aryl or heteroaryl, alone or as part of another group, in R_1 or R_2 in turn may be substituted in one or more postions, independently of

each other by C_{1-4}-alkyl, C_{1-4}-alkoxy, halogen, trifluoromethyl, cyano, hydroxy or dimethylamino; and

R_5 and R_6 independently of each other are hydrogen, methyl or ethyl, or together with the nitrogen atom to which they are bound form a pyrrolidine, piperazine, morpholine, thiomorpholine or a piperidine ring;

~~and~~ or a pharmaceutically acceptable salt, ~~hydrate,~~ geometrical isomer, tautomer, optical isomer, or *N*-oxide ~~or prodrug~~ form thereof.

2. (Withdrawn) The compound according to claim 1, wherein X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative.

3. (Withdrawn) The compound according to claim 1, wherein formula (I) represents a 4-trifluoromethylpyridine derivative.

4. (Cancelled)

5. (Original) The compound according to claim 1 wherein R_3 is hydrogen and R_1 or R_2 is selected from



6. (Original) The compound according to claim 1 wherein R_1 or R_2 is selected from



and where R_3 is hydrogen and R_4 is selected from hydrogen, methyl or ethyl.

7. (Original) The compound according to claim 1 wherein R_1 or R_2 is



and where R_3 is hydrogen and R_4 is selected from hydrogen, methyl or ethyl.

8. (Original) The compound according to claim 1, wherein R_1 or R_2 is selected from



9. (Currently Amended) The compound according to claim 1, which is selected from the group consisting of:

4-(Benzyloxy)-2-(1-piperazinyl)pyrimidine,

4-[(2-Methoxybenzyl)oxy]-2-(1-piperazinyl)pyrimidine, and

2-{[3-(Benzyloxy)benzyl]oxy}-4-(1-piperazinyl)pyrimidine,

~~and~~ or a ~~their~~ pharmacologically acceptable ~~salts~~ salt thereof ~~and solvates~~.

10. (Original) A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient, together with a pharmaceutically acceptable carrier.

11. (Cancelled) .

12. (Cancelled)

13. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ an eating disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

14. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ obesity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

15. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ a memory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

16. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ a mood disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

17. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ an anxiety disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

18. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is selected from~~ sexual dysfunctions, epilepsy ~~and~~ or urinary

disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

19. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

20. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ substance abuse, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

21. (Currently Amended) A ~~The~~ method for the treatment of ~~according to claim 11, wherein the medical condition is~~ schizophrenia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

22. (Currently Amended) A method of making a compound of claim 1, the method comprising:

(a) ~~taking~~ converting a compound of the following formula:



wherein

~~(i) X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative, or~~

~~(ii) X represents C-CF_3, Z represents CH, and Y represents nitrogen, forming a 4-trifluoromethylpyridine derivative, or~~

~~(iii)~~ Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein

each Hal is independently a halogen;

to a compound of formula (IX):



(IX)

wherein R_2 is as defined in claim 1 and with the proviso that R_2 is not any of the following groups:



, , ,or ;and

(b) contacting the compound of formula (IX) with a compound selected from the group consisting of:



and



(XI)

;

or

(a') converting a compound of the following formula:



wherein Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein each Hal is independently a halogen;

to a compound of formula (XIII):



(XIII)

wherein Am is an amine residue selected from the group consisting of:



, ,or ;and

(b') converting the compound of formula (XIII) to a compound of the following formula:



wherein R_1 is as defined in claim 1 and with the proviso that R_1 is not any of the following groups:



, ,or ;

~~with and reacting the compound with one or more chemical reagents in one or more steps to produce~~ thereby producing a compound of claim 1.

23. (Cancelled)

24. (Cancelled)

25. (Original) The compound according to claim 1, wherein R_3 is an acyl- or alkoxycarbonyl group forming a cleavable amide or carbamate linkage.

26. (New) The method of claim 15, wherein the memory disorder is Alzheimer's disease.

27. (New) The method of claim 16, wherein the mood disorder is depression.